BIOMAKERS and TOPAZIUM Unveil Groundbreaking AI Collaboration to Enhance NSCLC Immunotherapy
2024年8月6日 - 10:15PM
ビジネスワイヤ(英語)
BIOMAKERS, a Precision Medicine & Biotech Company
that supports data-driven Drug Development globally, and
TOPAZIUM, an AI-driven healthtech company specializing in
drug discovery and human wellbeing, have announced the results of
their innovative collaborative project. This partnership showcases
the power of AI systems in leveraging real-world DNA sequencing
data to identify novel targets aimed at improving the efficacy of
immunotherapy for non-small cell lung cancer (NSCLC) treatment. The
findings were presented at the prestigious 2024 American Society of
Clinical Oncology (ASCO) meeting in Chicago.
The study used Whole Exome Sequencing (WES) data from biopsies
of squamous and adenocarcinoma NSCLC processed through
BIOMAKERS' advanced DNA sequencing platforms. The data was
then analyzed using GFPrint™, a proprietary algorithm developed by
TOPAZIUM, that generates virtual representations of tumor
exomes in a latent space defined by the genetic features of the
samples.
“The advent of drugs targeting the PD-1/PD-L1 axis has
revolutionized NSCLC treatment. Although promising, individual
responses to these therapies can vary, and we believe this ongoing
project will help to better understand mechanisms involved in
PD1/PD-L1 expression, optimize treatment protocols, and identify
which patients are most likely to benefit from these therapies. In
this study, DNA sequencing and GFPrint™ were employed to identify
mutations in genes linked to PD-L1 expression in NSCLC
adenocarcinoma tumor samples,” said Dr. Rubén Salanova, Chief
Medical Officer & Co-Founder of BIOMAKERS.
“Using this strategy, we have identified a subpopulation of
adenocarcinoma patients with increased PD-L1 expression levels,
enriched in non-silent mutations of 10 genes of interest, mostly
included in the HIF-1α signaling pathway. Notably, 6 of these
mutated genes (PIK3R1, HK1, NOS2, NRAS, BRAF, ITGA1) were uniquely
found in adenocarcinomas” said Juan Manuel Domínguez, Head of
Preclinical & Biostatistics at TOPAZIUM.
“All these newly identified genes deserve further studies to
validate them as potential targets for pharmacological intervention
concomitant with PD-1/PD-L1 blockade, and as potential biomarkers
for patient selection to improve the efficiency of immunotherapy in
NSCLC treatment,” added Andrea Mendoza, Head of R&D at
BIOMAKERS.
For more details, the abstract can be accessed at:
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13600 For
more information about GFPrint™, visit:
https://www.biorxiv.org/content/10.1101/2024.03.08.584090v4
About BIOMAKERS:
BIOMAKERS is an Oncology Precision Medicine Company with
a Comprehensive Genomic Platform and reach throughout LATAM,
delivering care-changing solutions. In addition to its strong focus
on physician support and patient care, their Life Science division
partners with biopharma companies to advance R&D programs by
providing support for Drug Discovery and Drug Development. This
innovative work is enabled by direct partnerships with renowned
Health Institutions across 17 different countries.
contacto@biomakers.net
About TOPAZIUM:
TOPAZIUM is committed to supporting medical research with
artificial intelligence (AI) through state-of-the-art analytical
tools. They have developed a comprehensive AI engine that utilizes
multiple medical data types to assist in identifying new disease
patterns and the most promising therapeutic approaches, striving to
achieve one of the most challenging global goals: health for
all.
info@topazium.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801508303/en/
For media inquiries, contact Agustín Vidal:
adominguezvidal@biomakers.net